Clinical Trial Update: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating durvalumab with oleclumab or durvalumab with monalizumab after concurrent chemoradiation in stage III unresectable non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Monalizumab (monalizumab)
• Oleclumab (oleclumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING